Santen Pharmaceutical Co., Ltd. (4536) Press Release
Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
Filed with TSE ·
6ix hasn’t read this filing yet.
Earlier from Santen Pharmaceutical
- Santen Pharmaceutical: New Drug Application Filing Accepted for Review in China for STN1012700 (Atropine Sulfate Ophthalmic Solution 0.025%), an Ophthalmic Solution to Slow the Progression of Myopia
- Summary of Consolidated Financial Results for the Three Months Ended June 30, 2026 (IFRS)
- Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan
- Santen Pharmaceutical: China Signs Exclusive Distribution and Promotion Agreement for Five Marketed Glaucoma Eyedrops Products in the Chinese Mainland